209 related articles for article (PubMed ID: 15248414)
1. [No improvement of lipodystrophy syndrome in an HIV-infected patient].
Lanzafame M; Faggian F; Lattuada E; Antolini D; Concia E
Recenti Prog Med; 2004 Jun; 95(6):312-3. PubMed ID: 15248414
[TBL] [Abstract][Full Text] [Related]
2. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis.
Domingo P; Vidal F; Domingo JC; Veloso S; Sambeat MA; Torres F; Sirvent JJ; Vendrell J; Matias-Guiu X; Richart C;
Eur J Clin Invest; 2005 Dec; 35(12):771-80. PubMed ID: 16313254
[TBL] [Abstract][Full Text] [Related]
3. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
Maher B; Lloyd J; Wilkins EG; Fraser WD; Back D; Park BK; Pirmohamed M
Antivir Ther; 2004 Dec; 9(6):879-87. PubMed ID: 15651746
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1/HAART-associated lipodystrophy.
Giralt M; Domingo P; Guallar JP; Rodriguez de la Concepción ML; Alegre M; Domingo JC; Villarroya F
Antivir Ther; 2006; 11(6):729-40. PubMed ID: 17310817
[TBL] [Abstract][Full Text] [Related]
5. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.
Hirsch HH; Battegay M
Infection; 2002 Oct; 30(5):293-8. PubMed ID: 12382089
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
[TBL] [Abstract][Full Text] [Related]
7. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
[TBL] [Abstract][Full Text] [Related]
9. What does the term "HIV-associated lipodystrophy" mean?
Marcason W
J Am Diet Assoc; 2009 Feb; 109(2):364. PubMed ID: 19167963
[No Abstract] [Full Text] [Related]
10. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand.
Lee B; Aurpibul L; Sirisanthana V; Mangklabruks A; Sirisanthana T; Puthanakit T
HIV Med; 2009 Feb; 10(2):72-8. PubMed ID: 19018877
[TBL] [Abstract][Full Text] [Related]
11. [Criteria for AIDS-prices 2003. Why does HAART therapy in HIV patients cause fat catabolism?].
Urologe A; 2003 Sep; 42(9):1254. PubMed ID: 14619845
[No Abstract] [Full Text] [Related]
12. Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients.
Guallar JP; Cano-Soldado P; Aymerich I; Domingo JC; Alegre M; Domingo P; Villarroya F; Javier Casado F; Giralt M; Pastor-Anglada M
Antivir Ther; 2007; 12(6):853-63. PubMed ID: 17926640
[TBL] [Abstract][Full Text] [Related]
13. Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sevastianova K; Sutinen J; Kannisto K; Hamsten A; Ristola M; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E85-91. PubMed ID: 18430964
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity.
ter Hofstede HJ; Burger DM; Koopmans PP
Neth J Med; 2003 Dec; 61(12):393-403. PubMed ID: 15025414
[No Abstract] [Full Text] [Related]
15. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
[TBL] [Abstract][Full Text] [Related]
16. [Award of the 2003 AIDS Prize. Why doesn HAART therapy induce lipodystrophy in HIV positive patients?].
HNO; 2003 Jul; 51(7):543. PubMed ID: 12916494
[No Abstract] [Full Text] [Related]
17. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
18. [Lipodystrophy syndrome of patients infected by HIV receiving antiretroviral treatment].
Viard JP
Journ Annu Diabetol Hotel Dieu; 2003; ():111-23. PubMed ID: 12868306
[No Abstract] [Full Text] [Related]
19. Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy.
Sutinen J; Yki-Järvinen H
Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E687-92. PubMed ID: 17062843
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.
Kong HH; Myers SA
Dermatol Ther; 2005; 18(1):58-66. PubMed ID: 15842613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
